FLC
CERO

Fifth Lane Capital’s CERo Therapeutics CERO Stock Holding History

Fifth Lane Capital’s Portfolio CERO Stock Details CERO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-38
Closed -$6.89K – 57
2024
Q3 		$6.89K Hold
38
– – 0.02% 46
2024
Q2 		$0 Buy
+38
New +$88.3K ﹤0.01% 174

Other funds holding CERO

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.99% 1-Year Est. Return
APP
Avantax Planning Partners Dubuque, Iowa $4.02B AUM 20% 1-Year Est. Return
CSS
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 28.97% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SM
Selkirk Management Chatham, New Jersey $294M AUM 26.84% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Fifth Lane Capital's CERO Position: Q4 2024 in Review

Fifth Lane Capital sold out of CERo Therapeutics (CERO) in Q4 2024, closing a stake of 38 shares — an estimated $6.89K sold.

Fifth Lane Capital first reported a position in CERO in Q2 2024 and held it in 2 quarters. The position peaked at $6.89K in Q3 2024. 18 funds tracked by Wall St. Rank hold CERO as of Q4 2024.

  • Fifth Lane Capital reported no remaining CERo Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Fifth Lane Capital sold 38 CERo Therapeutics shares in Q4 2024, an estimated $6.89K.
  • Fifth Lane Capital first reported a position in CERo Therapeutics in Q2 2024 and held it in 2 quarters.
  • Fifth Lane Capital's CERo Therapeutics position peaked at $6.89K in Q3 2024.
  • 18 funds tracked by Wall St. Rank held CERo Therapeutics as of Q4 2024.

Based on Fifth Lane Capital's 13F filing for Q4 2024, filed 14 Feb 2025.